How the May 503B proposal affects HIMS, Mochi, and the DTC compounded GLP-1 market

Direct-to-consumer telehealth platforms have built sub-$200/month compounded GLP-1 access on top of the 503B outsourcing-facility supply chain. The FDA's May 4 proposal materially threatens that pipeline.

Who is exposed

Hims & Hers Health (HIMS): largest DTC compounded-GLP-1 distributor; 503B-dependent. Mochi: focused weight-loss telehealth, similar exposure. Henry Meds: similar. Smaller players (Ro, Calibrate) have hybrid models with branded-Wegovy access channels that partially insulate them.

What 503A fallback looks like

503A patient-specific compounding under medical necessity remains permitted. The throughput and cost structure differ: 503A pharmacies process per-patient prescriptions rather than bulk batches, which is slower and typically more expensive. Pricing under a 503A-only model would likely settle in the $400-600/month range vs current ~$200/month.

Timeline reality

Comment period closes August 3, 2026. Final rule publication: late 2026 or early 2027. Effective date: 6-12 months post-final-rule for most provisions. Patients on compounded GLP-1s through 2026 are unlikely to see immediate disruption; transition planning over the 12-18 month horizon is the practical question.

What we will be tracking

Earnings calls from HIMS and Novo (NVO) for management commentary on the proposal's impact on DTC volumes and branded-Wegovy demand respectively. Court filings if the rule is challenged. State pharmacy board guidance on the 503A medical-necessity standard.